RBC Capital analyst Alistair Campbell initiated coverage of Pharming with an Outperform rating and EUR 1.80 price target. The analyst says approval of Joenja will unlock the company’s next leg of growth. Joenja, a treatment for rare immunodeficiency disease, could double Pharming revenue by 2027, the firm predicts. It is confident on Pharming’s margin outlook even as the company invests in the Joenja launch.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PHAR:
- Pharming price target raised to $40 from $36 at Oppenheimer
- Pharming up 22% after resuming trading following announcement of FDA approval
- Pharming announces FDA approval of Joenja
- Pharming announces first patient enrolled in leniolisib trial
- Pharming announces CHMP decision to shift leniolisib MAA to standard review
